CryoPort, Inc. (NASDAQ:CYRX) Director Sells $93,380.21 in Stock

CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) Director Ramkumar Mandalam sold 13,321 shares of CryoPort stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $7.01, for a total transaction of $93,380.21. Following the completion of the sale, the director now directly owns 73,056 shares of the company's stock, valued at $512,122.56. The trade was a 15.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Ramkumar Mandalam also recently made the following trade(s):

• On Friday, June 13th, Ramkumar Mandalam sold 624 shares of CryoPort stock. The stock was sold at an average price of $6.80, for a total transaction of $4,243.20.
• On Thursday, June 12th, Ramkumar Mandalam sold 1,895 shares of CryoPort stock. The shares were sold at an average price of $7.01, for a total transaction of $13,283.95.
• On Wednesday, June 11th, Ramkumar Mandalam sold 8,193 shares of CryoPort stock. The stock was sold at an average price of $7.06, for a total value of $57,842.58.
• On Monday, June 9th, Ramkumar Mandalam sold 5,622 shares of CryoPort stock. The stock was sold at an average price of $7.06, for a total value of $39,691.32.

CryoPort Stock Up 1.6%

NASDAQ CYRX traded up $0.12 during trading hours on Friday, hitting $7.41. The company had a trading volume of 1,888,642 shares, compared to its average volume of 516,477. CryoPort, Inc. has a fifty-two week low of $4.58 and a fifty-two week high of $9.78. The company has a market capitalization of $371.54 million, a price-to-earnings ratio of -3.17 and a beta of 1.85. The company has a debt-to-equity ratio of 0.51, a current ratio of 5.56 and a quick ratio of 5.24. The firm's 50 day moving average is $6.36 and its 200 day moving average is $6.68.

CryoPort (NASDAQ:CYRX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.01. CryoPort had a negative return on equity of 11.03% and a negative net margin of 50.15%. The firm had revenue of $41.04 million during the quarter, compared to the consensus estimate of $56.19 million. Sell-side analysts anticipate that CryoPort, Inc. will post -0.99 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CYRX has been the subject of a number of research analyst reports. Morgan Stanley dropped their price objective on CryoPort from $8.00 to $7.00 and set an "equal weight" rating for the company in a report on Monday, May 5th. UBS Group upped their price objective on CryoPort from $10.00 to $11.00 and gave the stock a "buy" rating in a report on Tuesday, April 1st. Needham & Company LLC restated a "buy" rating and set a $11.00 price objective on shares of CryoPort in a report on Thursday, May 8th. Guggenheim restated a "buy" rating and set a $10.00 price objective on shares of CryoPort in a report on Wednesday, April 16th. Finally, Roth Mkm restated a "buy" rating and set a $15.00 price objective on shares of CryoPort in a report on Tuesday, April 1st. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $11.00.

Institutional Trading of CryoPort

Large investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers increased its holdings in CryoPort by 23.8% in the 1st quarter. Rhumbline Advisers now owns 78,320 shares of the company's stock valued at $476,000 after purchasing an additional 15,036 shares in the last quarter. Graham Capital Management L.P. boosted its position in CryoPort by 24.9% in the 4th quarter. Graham Capital Management L.P. now owns 28,460 shares of the company's stock valued at $221,000 after buying an additional 5,667 shares during the last quarter. Lazard Asset Management LLC purchased a new position in CryoPort in the 4th quarter valued at about $51,000. ProShare Advisors LLC purchased a new position in CryoPort in the 4th quarter valued at about $95,000. Finally, Price T Rowe Associates Inc. MD boosted its position in CryoPort by 8.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 60,003 shares of the company's stock valued at $467,000 after buying an additional 4,902 shares during the last quarter. 92.90% of the stock is currently owned by institutional investors and hedge funds.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.